Evolus (EOLS) Operating Income Growth (3y) (2020 - 2026)
Evolus (EOLS) Operating Income Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.51 Bn | 87.64 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.21 Bn | 1.97 Bn | 273.62% |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn | 3.84% |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn | -59.82% |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn | 4.63% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.25 Bn | 18.44 Bn | 1.16 Bn | -30.05% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.48 Bn | 800.70 Mn | 54.58% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 40.17% |
| 10 | Evolus | 400.90 Mn | 351.11 Mn | 48.90 Mn | 17.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.15% |
| Dec 31, 2025 | 33.83% |
| Sep 30, 2025 | 13.71% |
| Jun 30, 2025 | 21.80% |
| Mar 31, 2025 | 0.60% |
| Dec 31, 2024 | 49.56% |
| Sep 30, 2024 | 6.80% |
| Jun 30, 2024 | 20.44% |
| Mar 31, 2024 | -45.99% |
| Dec 31, 2023 | 56.92% |
| Sep 30, 2023 | -15.34% |
| Jun 30, 2023 | 7.15% |
| Mar 31, 2023 | 11.54% |
| Dec 31, 2022 | 5.35% |
| Sep 30, 2022 | 10.71% |
| Jun 30, 2022 | 15.98% |
| Mar 31, 2022 | 15.13% |
| Dec 31, 2021 | -12.96% |
| Sep 30, 2021 | -18.48% |
| Jun 30, 2021 | 1.70% |